The list of drugs which can trigger malignant hyperpyrexial reactions is well known and includes the volatile anaesthetic agents, the depolarising muscle relaxants and many others. Emotional stress, exercise and viral infections have also been shown to be involved in causing malignant hyperpyrexia. U In this case report, the safe use of propofol (2,6,diisopropylphenol) during cardiopulmonary bypass in a patient susceptible to malignant hyperpyrexia IS described.
CASE REPORT
A 41-year-old, 87 kg male with ischaemic heart disease presented for a single graft to the right coronary artery. Cardiac catheterisation had shown an occluded right coronary artery with reasonable left ventricular function (ejection fraction greater than 50%). Three years previously he had undergone an operation for a cerebellar haemangioblastoma. Following suxamethonium and halothane, he developed ventricular tachycardia, multifocal ventricular extrasystoles, hypercarbia despite hyperventilation and hyperkalaemia. On this basis, a diagnosis of MH was made and confirmed by positive halothane and caffeine contracture tests. Before induction of anaesthesia the usual precautionary measures for dealing with hyperpyrexial reactions were taken. Ice and cooled intravenous fluids were available. The patient was placed on a cooling blanket and dantrolene, verapamil, sodium bicarbonate 8.4%, dextrose 50% and actrapid insulin were all available for use.
A vapour-free anaesthetic machine with a new circuit was used in the anaesthetic room, and in the theatre a vapour-free SiemensElema Servo 900 B ventilator was used. The oxygenator used was a Dideco-Hiflex bubble oxygenator with disposable fittings. A vapouriser was not included in the circuit.
The patient's ECG was monitored and a left radial artery cannula was inserted to measure blood pressure and sample arterial blood. A right internal jugular cannula was inserted. Oesophageal and nasal thermistor probes were used and the patient's bladder catheterised. Inspired oxygen and end-tidal carbon dioxide were measured.
After premedication with papaveretum, 15 mg one hour preoperatively, anaesthesia was induced with thiopentone 3 mg/kg. The patient was intubated after phenoperidine 8 mg and pancuronium 8 mg had been given, and was ventilated to normocapnoea with nitrous oxide and 30% oxygen. A propofol infusion controlled by an IV AC 531 volumetric pump was started and continued throughout the procedure. Infusion rates varied according to systolic blood pressure and ranged from 100-150 mg/hour, with increased rates up to 300 mg/hour for short durations after bypass to reduce the elevated blood pressure.
The bubble oxygenator was primed with Hartmann's solution 2000 ml, and heparin 6000 IU, pancuronium 4 mg and phenoperidine 2 mg were added to the prime. Cardiopulmonary bypass was instituted without problems and the patient was cooled to 32 degrees Celsius. The heart was arrested with St. Thomas' cardioplegic solution in Ringers solution 1000 ml.
Rewarming was started 10 minutes after starting bypass using the integral heat exchanger in the oxygenator. Electromechanical activity returned, initially in ventricular fibrillation requiring internal defibrillation (30 joules) for correction to sinus rhythm, which was subsequently maintained. Both nasopharyngeal and oesophageal temperatures did not exceed 36.5 degrees Celsius during the procedure. Bypass was discontinued uneventfully. The total time on bypass was 30 minutes and the aortic crossclamp time was 16 minutes.
The postoperative course was stable, with the patient remaining on a ventilator for sever.. hours. A propofol infusion was used for sedation and a total dose of 1300 mg (140 mg/hour) was given over a period of nine hours. The patient had additional papaveretum for analgesia.
The temperature was monitored for 24 hours postoperatively. The core temperature rose to 38°C three hours after returning from Anaesthesia and Intensi.'e Care, Vol. 16 , No. 4, November, 1988 theatre but this settled with fan cooling. There were no other signs to herald the onset of a hyperthermic state. This mild temperature rise was considered normal and is not unusual after cardiopulmonary bypass.
The acid-base status of the patient was monitored half-hourly from the start of the anaesthetic. There was no evidence of respiratory or metabolic acidosis detected. Serum potassium and sodium levels remained stable. The patient returned to the ward after 24 hours of monitoring in the Intensive Care Unit, with no evidence of malignant hyperpyrexia.
DISCUSSION
Malignant hyperpyrexial reactions have been reported in patients while on cardiopulmonary bypass. 3 The risk of developing a hyperpyrexial reaction would be reduced by angioplasty under local anaesthesia. Angioplasty is not recommended with long-standing disease where the vessel is occluded or calcified,4 and was thus unsuitable in this case. There is one previous report of the safe use of propofol in an unconfirmed case of malignant hyperpyrexia. 5 In patients susceptible to malignant hyperpyrexia, there are no reported cases of avoiding pre-treatment with dantrolene before cardiac surgery requiring cardiopulmonary bypass.
Since malignant hyperpyrexia was first described in 1962 by Denborough et There has been no reported case to date of
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propofol triggering porcine malignant hyperpyrexia syndrome. In vitro tests on muscle tissue from hyperpyrexia-susceptible patients and pigs exposed to propofol did not cause contractures. 14.15 Propofol has been used in continuous infusions for total intravenous anaesthesia and for sedation in patients on ventilators in intensive care units. '6 . '7 Propofol has been used successfully as an induction agent for cardiopulmonary bypass, but not as the main agent to ensure unconsciousness. 18 The practice in our unit is to electively ventilate patients postoperatively until peripheral and core temperatures are normal, the cardiovascular system stable, with no evidence of bleeding and normal muscle tone has returned. The duration of ventilation can be reduced by using a propofol infusion for sedation postoperatively.
Recovery time is shorter after a single bolus of propofol than after a propofol infusion. 19 This is thought to be due to tissue accumulation decreasing the elimination rate. The pharmacokinetic profile of propofol remains linear over infusion rates up to 9 mg/kg/hr due to its high systemic clearance. 2o . 21 In patients with poor left ventricular function, the fall in systemic vascular resistance found with the use of propofol can cause unacceptable falls in blood pressure. 18 Malignant hyperpyrexia can be prevented in the porcine model by dantrolene prophylaxis,22 but in the susceptible human prophylaxis is not completely reliable. 23 The use of dantrolene preoperatively has been advocated by many authors, but the dose and route of administration has been debated for some time.2.23.24 The recommended practice involves one or two days of oral dantrolene up to 4 mg/kg/day as well as an intravenous dose of 1.0 mg/kg at induction, but this is now open to question. 25 This dose approaches the upper limit tolerated by patients with increasing incidence of adverse effects and does not guarantee prophylactic plasma concentrations of dantrolene. 25 To avoid the side-effects of oral dantrolene but provide adequate prophylaxis, an intravenous dose of2.5 mg/kg at induction has been recommended. 24 . 25 The true value of dantrolene pre-treatment has been questioned after the reports of malignant hyperpyrexial reactions developing with dantrolene pre-treatment and a triggerfree anaesthetic. 26 . 27 Britt, in a review of dantrolene, suggests that the value of pretreatment remains unknown and that its use should be reserved for special cases.23 It has been suggested that, given a trigger-free 'safe' anaesthetic with close monitoring and intravenous dantrolene available, prophylactic administration of dantrolene may be unnecessary.2J.25 This is, however, controversial.
The safe use of propofol, both intra-and postoperatively, in a malignant hyperpyrexia susceptible patient undergoing surgery involving cardiopulmonary bypass is reported. The provision of safe anaesthesia in susceptible patients is a top priority for today's anaesthetist. Propofol may, with time and further experience, be added to our armamentarium in dealing with this formidable problem.
prognosis. I The combined use of inotropic agents and vasodilators has proved useful in patients with severe left ventricular dysfunction. Use of vasodilator therapy, however, may be limited by the occurrence of hypotension and patients with ischaemic heart disease may be sensitive to the chronotropic and dysrhythmogenic effects of catecholamines. We report the successful management of such a case with the combined use of noradrenaline, amrinone and nitroglycerin.
